Man you hit the hammer on the head... We set our price, and we stay true to your goals and folks $1.00 is the right price for most. And it sounds fair to most...
YOU WILL NOT FIND THIS NEWS ON IHUB OR ANYWHERE ELSE. WE HAVE BRAINS LOADING VDRM SOAKING UP OVER 18 MILLION SHARES AND COUNTING. WE CANNOT BE RATTLED. NO ONE KNOWS ABOUT VDRM. THEIR DRUG HAS BEEN TESTE4D ANDE IS 99% EFFECTICE AGAINST ALL TYPES OF BACTERIA. 99%! 25 CENTS COMINGGGGG!!!??
TetraStem(TM) Antibiotic Continues to Demonstrate Treatment Success Leading Management to Explore Partnerships With Big Pharmaceutical Companies GlobeNewswire via CMTX - Tue Dec 09, 8:44AM CST
ViaDerma, Inc. (OTC:VDRM), a specialty pharmaceutical company devoted to bringing new products to market, recently announced TetraStem, a topical liquid tetracycline-based antibiotic that uses a patent-pending innovative transdermal delivery system that can convert oral medication active ingredients into topical drugs. The drug is FDA-registered as a first aid antibiotic to help prevent skin infection in minor cuts, scrapes, and burns, but importantly, has also shown to be effective in fighting more harmful forms of staphylococcus aureus infections, which are commonly known as 'staph infections.'
Due to mutations of historically more common forms of staph infections, according to the Mayo Clinic, certain strains of staph bacteria have become resistant to the antibiotics commonly used to treat staph infections. Without the introduction of novel antibiotic treatments, infections can spread and sometimes become life threatening.
ViaDerma's studies involving TetraStem continue to demonstrate efficacy in terms of treating novel forms of staff infections not responding to treatment using current standard of care antibiotics. "We are enthusiastic about the results we have achieved to date in terms of the anecdotal feedback we have received from patients that have been treated with TetraStem," said Dr. Christopher Otiko, ViaDerma's founder and CEO.
"Given the successful implementation of TetraStem to date and the demonstrated need for new, more potent forms of antibiotics, in addition to deploying TetraStem at select hospitals, ViaDerma management will explore partnerships with large pharmaceutical companies in order to accelerate the application of TetraStem at this time," said Dr. Otiko.
According to the Financial Times, yesterday's announcement of a $9.5B takeover of Cubist Pharmaceuticals, Inc. by Merck & Co. Inc., "highlights renewed interest from big pharma in the long-neglected market for antibiotics. [T]here have been signs of a revival in the past two years with Roche, GlaxoSmithKline and Sanofi all pledging fresh investment or forging research partnerships to develop new bug fighting drugs."
The World Health Organization (WHO) warned in April that antibiotic resistance "threatens the achievements of modern medicine." Without urgent action, it said, the world was "headed for a post-antibiotic error, in which common infections and minor injuries, which have been treatable for decades, can once again kill." Currently, antibiotic-resistant infections kill approximately 50,000 people a year in the United States and Europe and that number is on the rise, according to the WHO.
News 
Market Data 
Discover 
